AU Patent

AU2020232246A1 — Methods of treating disease with levoketoconazole

Assigned to Strongbridge Dublin Ltd · Expires 2021-10-07 · 5y expired

What this patent protects

Provided herein is a method of administering levoketoconazole, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered a multidmg and toxin extrusion transporter 1 (MATE1) substrate or an organic cation transport…

USPTO Abstract

Provided herein is a method of administering levoketoconazole, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered a multidmg and toxin extrusion transporter 1 (MATE1) substrate or an organic cation transporter 2 (OCT2) substrate.

Drugs covered by this patent

Patent Metadata

Patent number
AU2020232246A1
Jurisdiction
AU
Classification
—
Expires
2021-10-07
Drug substance claim
No
Drug product claim
No
Assignee
Strongbridge Dublin Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.